Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

(2012) J. S. Powell et al.   BLOOD

Personalized prophylaxis

(2012) P. W. COLLINS   HAEMOPHILIA

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

(2011) S. Bjorkman et al.   BLOOD

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

(2011) H. Ostergaard et al.   BLOOD

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

(2011) C. Negrier et al.   BLOOD

Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010

(2011) J. UPRICHARD et al.   HAEMOPHILIA

Clinical severity of haemophilia A: does the classification of the 1950s still stand?

(2011) I. E. M. Den UIJL et al.   HAEMOPHILIA

Hemophilia: New Protein Therapeutics

(2011) S. W. Pipe   Hematology-American Society of Hematology Education Program

A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A

(2010) Michael Richards et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prophylaxis in the haemophilia population

(2010) V. S. BLANCHETTE   HAEMOPHILIA

Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis

(2010) D. V. K. QUON et al.   HAEMOPHILIA

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

(2010) P. W. COLLINS et al.   HAEMOPHILIA

Prophylactic therapy in haemophilia

(2009) Rolf Ljung   BLOOD REVIEWS

Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years

(2009) Sven Björkman et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

(2008) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS